This forgotten stock might be too risky even for contrarian investors.Inovio Pharmaceuticals (INO +0.58%) isn't a particularly well-known or prominent name in the biotech industry, but some may remember it as one of those smaller companies that sought to develop and market a coronavirus vaccine in the early years of the pandemic. Inovio's efforts were unsuccessful, and since then, the stock has lost significant market value. Will it continue moving in the wrong direction? Or is there a rebound in the cards? ...